AtriCure Inc.
FDA OKs AtriCure’s AF ablation post-approval study | Regulatory Roundup
Greatbatch proposes to mostly exit Switzerland for Indiana, Mexico | Wall Street Beat
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.
St. Jude Medical’s largest backer boosts stake by 30% | Wall Street Beat
St. Jude Medical‘s (NYSE:STJ) largest investor boosted its stake by more than 30%, to some 27.2 million shares, or about 10% of the medical device maker.
AtriCure soars on Street-beating Q1 results
AtriCure (NSDQ:ATRC) shares gained nearly 15% this morning after it reported lower-than-expected losses and record revenues of $17.5 million for the 1st quarter.
The West Chester, Ohio-based atrial fibrillation device maker reported losses of $1.6 million, or 10¢ per share, on sales of $17.5 million for the 3 months ended March 31, representing an 11.8% top-line increase.
Former Guidant sales rep gets green light to pursue lawsuit | Legal News
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
GE, Masimo ink OEM deal | Wall Street Beat
AtriCure’s Q4, 2011 losses widen, margins slip, shares gain anyway
AtriCure (NSDQ:ATRC) may have put up some red ink during the 4th quarter and 2011, but Wall Street investors remained unfazed today, sending shares up 3.5%.
That might be due to its king-of-the-hill status as the only company with a surgical cardiac ablation device on the U.S. market and its slow-but-steady plan to train surgeons on integrating the device into their practices.
Edwards to re-state financials | Wall Street Beat
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
CardioFocus launches pivotal trial for HeartLight ablation system
CardioFocus successfully treated the first patient in a pivotal trial of its HeartLight endoscopic ablation system for atrial fibrillation.
The HeartLight device is the first of its kind to to allow direct visualization of a beating heart in real time, without using radiation, to allow physicians to better aim delivery of ablation energy, according to a press release.